These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33728251)

  • 1. Biomarkers for prediction of skeletal disease progression in mucopolysaccharidosis type I.
    Lund TC; Doherty TM; Eisengart JB; Freese RL; Rudser KD; Fung EB; Miller BS; White KK; Orchard PJ; Whitley CB; Polgreen LE
    JIMD Rep; 2021 Mar; 58(1):89-99. PubMed ID: 33728251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression of Hip Dysplasia in Mucopolysaccharidosis Type I Hurler After Successful Hematopoietic Stem Cell Transplantation.
    Langereis EJ; den Os MM; Breen C; Jones SA; Knaven OC; Mercer J; Miller WP; Kelly PM; Kennedy J; Ketterl TG; O'Meara A; Orchard PJ; Lund TC; van Rijn RR; Sakkers RJ; White KK; Wijburg FA
    J Bone Joint Surg Am; 2016 Mar; 98(5):386-95. PubMed ID: 26935461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucopolysaccharidosis type I.
    Wraith JE; Jones S
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():102-6. PubMed ID: 25345091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory process and oxidative/nitrative stress: in vivo study in mucopolysaccharidosis type IV A patients under long-term enzyme replacement therapy.
    Aguilar Delgado C; Hammerschmidt T; Faverzini JL; Lopes F; Giugliani R; Baldo G; Vargas CR
    Arch Biochem Biophys; 2023 Mar; 737():109541. PubMed ID: 36754222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers of bone remodeling in children with mucopolysaccharidosis types I, II, and VI.
    Stevenson DA; Rudser K; Kunin-Batson A; Fung EB; Viskochil D; Shapiro E; Orchard PJ; Whitley CB; Polgreen LE
    J Pediatr Rehabil Med; 2014; 7(2):159-65. PubMed ID: 25096868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry.
    D'Aco K; Underhill L; Rangachari L; Arn P; Cox GF; Giugliani R; Okuyama T; Wijburg F; Kaplan P
    Eur J Pediatr; 2012 Jun; 171(6):911-9. PubMed ID: 22234477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure.
    Langereis EJ; Borgo A; Crushell E; Harmatz PR; van Hasselt PM; Jones SA; Kelly PM; Lampe C; van der Lee JH; Odent T; Sakkers R; Scarpa M; Schafroth MU; Struijs PA; Valayannopoulos V; White KK; Wijburg FA
    Orphanet J Rare Dis; 2013 Oct; 8():155. PubMed ID: 24088413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual α-L-iduronidase activity in fibroblasts of mild to severe Mucopolysaccharidosis type I patients.
    Oussoren E; Keulemans J; van Diggelen OP; Oemardien LF; Timmermans RG; van der Ploeg AT; Ruijter GJ
    Mol Genet Metab; 2013 Aug; 109(4):377-81. PubMed ID: 23786846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK.
    Moore D; Connock MJ; Wraith E; Lavery C
    Orphanet J Rare Dis; 2008 Sep; 3():24. PubMed ID: 18796143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome.
    Tomatsu S; Sawamoto K; Alméciga-Díaz CJ; Shimada T; Bober MB; Chinen Y; Yabe H; Montaño AM; Giugliani R; Kubaski F; Yasuda E; Rodríguez-López A; Espejo-Mojica AJ; Sánchez OF; Mason RW; Barrera LA; Mackenzie WG; Orii T
    Drug Des Devel Ther; 2015; 9():1937-53. PubMed ID: 25897204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiographic Findings of Mucopolysaccharidosis and Comparison with Bone Mineral Density: A Study from Southeastern Turkey.
    Ayaz E; Bozaci AE
    J Clin Densitom; 2022; 25(4):475-484. PubMed ID: 36100508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restricted joint range of motion in patients with MPS II: correlation with height, age and functional status.
    Marucha J; Jurecka A; Syczewska M; Różdżyńska-Świątkowska A; Tylki-Szymańska A
    Acta Paediatr; 2012 Apr; 101(4):e183-8. PubMed ID: 22077147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hip pathologies in mucopolysaccharidosis type III.
    Breyer SR; Vettorazzi E; Schmitz L; Gulati A; von Cossel KM; Spiro A; Rupprecht M; Stuecker R; Muschol NM
    J Orthop Surg Res; 2021 Mar; 16(1):201. PubMed ID: 33741007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A long term follow-up study of the development of hip disease in Mucopolysaccharidosis type VI.
    Oussoren E; Bessems JHJM; Pollet V; van der Meijden JC; van der Giessen LJ; Plug I; Devos AS; Ruijter GJG; van der Ploeg AT; Langeveld M
    Mol Genet Metab; 2017 Jul; 121(3):241-251. PubMed ID: 28552677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients.
    Tylki-Szymanska A; Marucha J; Jurecka A; Syczewska M; Czartoryska B
    J Inherit Metab Dis; 2010 Apr; 33(2):151-7. PubMed ID: 20217237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study of the safety and effect of adalimumab on pain, physical function, and musculoskeletal disease in mucopolysaccharidosis types I and II.
    Polgreen LE; Kunin-Batson A; Rudser K; Vehe RK; Utz JJ; Whitley CB; Dickson P
    Mol Genet Metab Rep; 2017 Mar; 10():75-80. PubMed ID: 28119823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth in individuals with attenuated mucopolysaccharidosis type I during untreated and treated periods: Data from the MPS I registry.
    Polgreen LE; Bay L; Clarke LA; Guffon N; Jones SA; Muenzer J; Flores AL; Wilson K; Viskochil D
    Am J Med Genet A; 2022 Oct; 188(10):2941-2951. PubMed ID: 35869927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers in patients with mucopolysaccharidosis type II and IV.
    Fujitsuka H; Sawamoto K; Peracha H; Mason RW; Mackenzie W; Kobayashi H; Yamaguchi S; Suzuki Y; Orii K; Orii T; Fukao T; Tomatsu S
    Mol Genet Metab Rep; 2019 Jun; 19():100455. PubMed ID: 30775257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of bone health in patients with mucopolysaccharidosis.
    Kor D; Bulut FD; Kılavuz S; Şeker Yılmaz B; Köşeci B; Kara E; Kaya Ö; Başaran S; Seydaoğlu G; Önenli Mungan N
    J Bone Miner Metab; 2022 May; 40(3):498-507. PubMed ID: 35066680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early disease progression of Hurler syndrome.
    Kiely BT; Kohler JL; Coletti HY; Poe MD; Escolar ML
    Orphanet J Rare Dis; 2017 Feb; 12(1):32. PubMed ID: 28193245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.